Five-Day Antiviral Infusion Safe for Long COVID, ERASE Trial Finds
A UK feasibility study found that giving long COVID patients a five-day intravenous antiviral was safe and doable — and many reported less fatigue, better quality of life and longer walking distances. Researchers now want a bigger randomized trial to prove whether the drug actually works.
- Original source: medicalxpress.com.
- The source published it on Nov 18, 2026 at 4:50 PM.
- Not verified by major outlets. This story may be false.
- No second outlet has reported it yet. Treat it as a single-source claim.
The ERASE LC trial has cleared its first hurdle. Delivering a five-day intravenous antiviral treatment to people with long COVID — and running all the assessments needed to measure it — was safe and feasible, researchers report in Oxford Open Immunology. The team behind it is now pushing for a larger randomized controlled trial to find out whether the treatment truly helps.
Seventy-three patients went through assessments at specialist university facilities and at the University of Exeter before receiving the antiviral drug intravenously for five consecutive days. Clinical teams from University Hospitals of Derby and Burton NHS Foundation Trust and Royal Devon University Healthcare NHS Foundation Trust ran the treatment, in collaboration with Aston University. The study, an open-label feasibility trial of remdesivir, began in September 2024, roughly five years after the global COVID-19 pandemic started.
The trial wasn't built to prove the drug works, but the exploratory measures still turned heads. Most participants reported less fatigue, a better quality of life and increased distance in a timed walking test. Long COVID is estimated to affect more than 2 million people in the UK, with symptoms ranging from extreme fatigue and breathlessness to palpitations and brain fog.
Professor Mark Faghy, professor of clinical exercise science at Loughborough University and a visiting professor at the University of Derby, called the results an important step forward. He stressed that ERASE was not designed to show whether the treatment caused the changes — only that the setup works — and said the findings give a strong rationale for a bigger randomized trial that can answer the question properly.
Professor Victoria Allgar, professor of medical statistics and director of PenCTU, said the trial's successful completion shows why feasibility studies matter: recruitment, treatment delivery, data collection and participant follow-up all proved workable in people living with long COVID, laying the foundation for a definitive trial.
TopicsERASE LC trial · remdesivir · long COVID · Mark Faghy · Victoria Allgar · Loughborough University · University of Exeter · Oxford Open Immunology
Source: medicalxpress.com
Written by AI from verified reporting.
More stories
- Health & science theguardian.com 0 viewsE coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise
- Health & science rarecancernews.com 2 viewsEU approves Rasonque for previously treated metastatic pancreatic cancer
- Health & science dailycoffeenews.com 2 viewsFDA Pullplug on Methylene Chloride Use, Decaf Ban Fight Continues
- Health & science wam.ae 2 viewsUAE drug regulator: no medical ads without approval, influencer promos banned

